Active Ingredient History
Cephalexin is a semisynthetic cephalosporin antibiotic intended for oral administration. In vitro tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cephalexin has been shown to be active against most strains of the following microorganisms both in vitro: Staphylococcus aureus (including penicillinase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains), Streptococcus pyogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Proteus mirabilis. Cephalexin is indicated for the treatment of the respiratory tract, skin and skin structure, bone and genitourinary tract infections when caused by susceptible strains of the designated microorganisms. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bacterial Infections (approved 1971)
Abscess (Phase 4)
Acute Kidney Injury (Phase 4)
Allergy and Immunology (Phase 4)
Anesthesia and Analgesia (Phase 3)
Anti-Infective Agents (Phase 1)
Arrhythmias, Cardiac (Phase 3)
Arthritis, Infectious (Phase 4)
Autoimmune Diseases (Phase 4)
Bacterial Infections (Phase 4)
Bone Diseases, Infectious (Phase 4)
Breast Diseases (Phase 4)
Breast Neoplasms (Phase 2)
Cellulitis (Phase 4)
Colonic Neoplasms (Phase 4)
Community-Acquired Infections (Phase 4)
Cystic Fibrosis (Phase 3)
Cystitis (Phase 4)
Dermatitis (Phase 2)
Dermatitis, Atopic (Phase 2)
Dermatology (Phase 4)
Diabetes Mellitus (Phase 4)
Eczema (Phase 2)
Endocarditis (Phase 4)
Enterobacteriaceae Infections (Phase 4)
Facial Injuries (Phase 4)
Finger Injuries (Phase 2)
Folliculitis (Phase 4)
Fractures, Bone (Phase 1/Phase 2)
Fractures, Open (Phase 4)
Genetic Predisposition to Disease (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
Hemodialysis, Home (Phase 4)
Infections ()
Inflammation (Phase 4)
Kidney Calculi (Phase 3)
Nasal Obstruction (Phase 3)
Nasal Surgical Procedures (Phase 3)
Obesity (Phase 4)
Osteomyelitis (Phase 4)
Pacemaker, Artificial (Phase 4)
Prostatic Hyperplasia (Phase 4)
Prosthesis-Related Infections (Phase 4)
Pyelonephritis (Phase 4)
Pyomyositis (Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Respiratory Tract Infections (Phase 1)
Sepsis (Phase 4)
Sick Sinus Syndrome (Phase 3)
Skin Diseases (Phase 2)
Skin Diseases, Bacterial (Phase 3)
Skin Diseases, Genetic (Phase 2)
Skin Diseases, Infectious (Phase 3)
Staphylococcal Infections (Phase 4)
Surgical Wound Infection (Phase 4)
Syncope (Phase 3)
Tobacco Use (Phase 4)
Tuberculosis, Pulmonary (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urinary Bladder, Overactive (Phase 1)
Urinary Tract Infections (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
